Advertisement

 

 

Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature.

Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature.
Author Information (click to view)

Patel RR, Presti R, Harrison LC, Powderly WG, Chan PA,


Patel RR, Presti R, Harrison LC, Powderly WG, Chan PA, (click to view)

Patel RR, Presti R, Harrison LC, Powderly WG, Chan PA,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Antiviral therapy 2017 11 23() doi 10.3851/IMP3208

Abstract

Pre-exposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF), can effectively prevent HIV acquisition. However, TDF can cause changes in bone mineral density (BMD). There is little information on the use of PrEP among patients with bone disease. We present a case report of a female with pre-existing osteoporosis who was prescribed PrEP. Over the course of nine months of consistent PrEP use, verified by dried blood spot testing, we report a lack of BMD changes on serial dual-emission x-ray absorptiometry scans in this patient. This case can inform PrEP care for patients with pre-existing bone disease.

Submit a Comment

Your email address will not be published. Required fields are marked *

2 × five =

[ HIDE/SHOW ]